Use of tamoxifen in pT1a-pT1b, pN0 breast cancer
| Autor: | C. De Luca Cardillo, Calogero Saieva, Gabriele Simontacchi, P. Ponticelli, Alessandra Galardi, Fabiola Paiar, Giampaolo Biti, Lorenzo Livi, Monica Mangoni, L. Paoletti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Disease specific survival Antineoplastic Agents Breast Neoplasms Breast cancer Internal medicine Local recurrence Medicine Humans Aged Neoplasm Staging Proportional Hazards Models Retrospective Studies Univariate analysis Hormonal business.industry Cancer Tamoxifen Combined Modality Therapy Female Middle Aged Neoplasm Recurrence Local Radiotherapy Dosage Regression Analysis Survival Analysis Treatment Outcome Surgery General Medicine medicine.disease Radiation therapy Log-rank test Neoplasm Recurrence Local Local disease business medicine.drug |
| Popis: | To evaluate if in low-risk breast cancer patients (pT1a-pT1b, pN0) tamoxifen can reduce local recurrence and improve survival.Retrospectively 700 patients were analyzed. All patients were treated from 1980 to 2003 with conservative surgery plus radiotherapy at the University of Florence. No patients were treated with adjuvant chemotherapy. Tamoxifen was prescribed in 359 patients (51.3%). The crude probability of survival (or local recurrence) was estimated by using Kaplan-Meier method, and survival (or local recurrence) comparisons were carried out using Cox proportional hazard regression models.The univariate analysis for specific survival showed that only histological type and local recurrence were significant prognostic factors (log rank test: p=0.02 and p0.0001, respectively). The Cox regression model by stepwise selection confirmed lobular histological type (p=0.008; HR: 3.83, 95% CI: 1.31-11.21) and local recurrence (p0.001; HR: 9.05, 95% CI: 3.05-26.82) as independent prognostic factors for disease specific survival. For local disease free survival, multivariate analysis did not show any significant parameters.In our series tamoxifen did not seem to improve disease specific survival and local disease specific survival. The number of events in terms of death for cancer or in terms of local recurrence is too small in this group of patients. However, according to our results we suggest not to prescribe tamoxifen in patients affected by pT1a-pT1b, pN0 breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|